Uetz Quoted in The Wall Street Journal About Asset-Backed Loan Liquidations Amid Pandemic
06 May 2020
The Wall Street Journal
Partner Ann Marie Uetz was quoted in The Wall Street Journal article, “In a Pandemic, Food, Booze and Guns Retain Value Best,” about considerations for lenders when valuing asset-backed loans amid the pandemic if they need to liquidate borrowers inventories to try to recoup money owed to them. Certain asset categories like food and beverages, pharmaceuticals and firearms had the lowest appraisal risk and markets for those products are forecast to stabilize in the coming months. Apparel and footwear had the highest risk of losing their value, with a low projected stabilization rate, while auto parts, building supplies and lumber were in between.
For lenders with no choice but to sell assets that backed their loans, speed is key. “Speed is critically important, as assets can deteriorate from fair market value, to forced liquidation value, and ultimately to scrap value, fairly quick,” said Uetz.
People
Related News
26 September 2024
In the News
Gregory Marino on NIL Litigation – 'Schools want to know where the line is, and now everything is in flux'
Foley & Lardner LLP special counsel Gregory Marino shared insight on the growing complexities of collegiate sports in the ABA Journal article, "Money and litigation tangle with recent rules for college athletes' NIL deals."
24 September 2024
In the News
Thomas Ferrante Assesses Recent HHS OIG Report on Remote Patient Monitoring
Foley & Lardner LLP partner Thomas Ferrante commented on the recently released report on remote patient monitoring from the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Fierce Healthcare article, “HHS watchdog flags potential remote monitoring fraud. Stakeholders say concerns about misuse are overblown.”
20 September 2024
In the News
David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing
Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."